APAC Insurers & Employers Discuss Cost Risk Associated with Regenerative Medicine

APAC insurers and employers are currently dealing with a new challenge related to how they reimburse regenerative medicines that are increasingly close to being used in clinical practice. Regenerative medicine represents certain risks associated with the treatment itself and the reimbursement framework for it, which is currently under discussion.

The topic appears due to the growth of advanced therapies on the market of Asia-Pacific, making the private insurance sector consider whether it is possible to pay for therapies that offer a long-term medical potential but have high initial costs and unclear coverage standards.

Insurance companies in Asia-Pacific need to figure out how to classify regenerative medicines as either experimental care, specialty treatment or medically necessary intervention. The classification issue has been complicated since such treatment does not always fit traditional approaches to medication reimbursement. The issue involves additional laboratory services, extended monitoring or personalized manufacturing processes that cannot be assessed with a current code system.

Employers' interest in the issue is driven by their existing problems with healthcare funding. The increased healthcare costs put pressure on employee benefits, which means that there may arise differences between healthcare provision standards in countries where a company operates.

Insurers may also be concerned about long-term evidence development and the ability to evaluate a treatment's effectiveness properly. Some regenerative medicine offers a reduction in the disease burden in the long run, but there might be no easy way to measure its effectiveness or make a cost-benefit analysis at an early stage.

Public awareness about regenerative medicine also contributes to the discussion as patients can have misconceptions about coverage standards when dealing with such medicines at special clinics or via medical tourism. Therefore, it is important for insurers to introduce new mechanisms to reduce the risk of covering unnecessary therapies for employers.

In some cases, such mechanisms are implemented through narrower pathways for coverage or specific case assessments of regenerative medicines. While it helps to avoid risks for a while, it can lead to difficulties for healthcare providers that have trouble adjusting to the complex process of treatment provision.

Employers, who rely heavily on a highly skilled workforce, are interested in the reimbursement issue, particularly, those therapies that are used to recover from orthopedic conditions, degenerative diseases and cancers. However, workforce retention issues do not guarantee that finance specialists will have an easy time estimating the future costs of such treatments, given their unstable price pattern.

Regenerative medicine is also discussed in terms of growing healthcare inequalities as such advanced therapies may become accessible only to private healthcare and major urban centers if reimbursement standards develop unevenly in APAC. Such development can cause difficulties for smaller employers and public systems with little or no reimbursement frameworks and pricing strategies developed.